VCM
IBRX icon

Voleon Capital Management’s ImmunityBio IBRX Stock Holding History

Voleon Capital Management’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$8.88M Sell
1,157,158
-357,428
-24% -$2.45M 0.19% 119
2025
Q4 		$3M Buy
1,514,586
+1,498,332
+9,218% +$3.39M 0.06% 282
2025
Q3 		$40K Buy
+16,254
New +$41.9K ﹤0.01% 876

Other funds holding IBRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Voleon Capital Management's IBRX Position: Q1 2026 in Review

Voleon Capital Management reduced its ImmunityBio (IBRX) stake by 24% in Q1 2026, selling an estimated $2.45M and leaving 1,157,158 shares worth $8.88M. The position accounts for 0.19% of the portfolio, ranked #119.

Voleon Capital Management first reported a position in IBRX in Q3 2025 and has held it in 3 quarters since. 386 funds tracked by Wall St. Rank hold IBRX as of Q1 2026.

  • Voleon Capital Management held 1,157,158 shares of ImmunityBio worth $8.88M as of Q1 2026.
  • Voleon Capital Management sold 357,428 ImmunityBio shares in Q1 2026, an estimated $2.45M.
  • ImmunityBio made up 0.19% of Voleon Capital Management's portfolio in Q1 2026, its #119 holding.
  • Voleon Capital Management first reported a position in ImmunityBio in Q3 2025 and has held it in 3 quarters since.
  • 386 funds tracked by Wall St. Rank held ImmunityBio as of Q1 2026.

Based on Voleon Capital Management's 13F filing for Q1 2026, filed 15 May 2026.